Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Hsuan-Ming Yao"'
Autor:
Sarah Ruta Jones, Serafin Morales, Shahrzad Moosavi, Amy Freyman, Faith D. Ottery, Jeffrey Zhang, Hsuan-Ming Yao
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To evaluate the pharmacodynamics (PD), pharmacokinetics (PK), and safety of single and multiple doses of PF-06881894 (pegfilgrastim-apgf; Nyvepria™), a biosimilar to reference pegfilgrastim (Neulasta®), in women with non-distantly metastat
Autor:
Jeffrey Levy, Stuart Harris, Reginald Ewesuedo, Troy Borema, Shahrzad Moosavi, Thomas B. May, Jeffrey S. Thomas, Jeffrey Zhang, Hsuan-Ming Yao, Martin Summers
Publikováno v:
Advances in Therapy
PF-06881894 is a proposed biosimilar to pegfilgrastim (Neulasta®). This study evaluated the pharmacodynamic/pharmacokinetic (PD/PK) equivalence, immunogenicity, and safety of PF-06881894 vs pegfilgrastim reference products (US- and EU-Neulasta®) in
Autor:
Shahrzad Moosavi, Martin Summers, Jeffrey Levy, Thomas B. May, Troy Borema, Hsuan-Ming Yao, Jeffrey Zhang, Stuart Harris, Faith D. Ottery
Publikováno v:
BioDrugs. 33:207-220
Three comparative clinical studies assessed the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and safety of PF-06881893 (filgrastim-aafi; Nivestym™), a filgrastim biosimilar, versus US-licensed reference product (filgrastim; US-Neupo
Autor:
Hsuan-Ming, Yao, Faith D, Ottery, Troy, Borema, Stuart, Harris, Jeffrey, Levy, Tom B, May, Shahrzad, Moosavi, Jeffrey, Zhang, Martin, Summers
Publikováno v:
Biodrugs
Background Three comparative clinical studies assessed the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and safety of PF-06881893 (filgrastim-aafi; Nivestym™), a filgrastim biosimilar, versus US-licensed reference product (filgrasti
Publikováno v:
Clinical Neuropharmacology
Levodopa (LD) combined with a peripheral inhibitor of aromatic L-amino acid decarboxylase, such as carbidopa (CD), continues to be the most effective treatment of Parkinson disease and is well tolerated at all stages of the disease.1–3 Immediate-re
Publikováno v:
The Journal of Clinical Pharmacology. 55:995-1003
IPX066 (extended-release carbidopa-levodopa [ER CD-LD]) is an oral extended-release capsule formulation of carbidopa and levodopa. The single-dose pharmacokinetics of ER CD-LD (as 2 capsules; total dose, 97.5 mg-390 mg CD-LD) versus immediate-release
Autor:
Suneel K. Gupta, Nishit B. Modi, Sherron Kell, Martin O'Connell, Ann Hsu, Hsuan‐Ming Yao, Leo Verhagen Metman, Aaron Ellenbogen, Robert A. Hauser
Publikováno v:
Movement Disorders. 26:2246-2252
The objective of the study was to compare the pharmacokinetics, motor effects, and safety of IPX066, a novel extended-release formulation of carbidopa-levodopa, with an immediate-release carbidopa-levodopa formulation in advanced Parkinson's disease.
Publikováno v:
Journal of Clinical Pharmacology
IPX066 (extended‐release carbidopa‐levodopa [ER CD‐LD]) is an oral extended‐release capsule formulation of carbidopa and levodopa. The single‐dose pharmacokinetics of ER CD‐LD (as 2 capsules; total dose, 97.5 mg‐390 mg CD‐LD) versus i
Publikováno v:
Food and Chemical Toxicology. 40:1901-1902
Publikováno v:
Food and Chemical Toxicology. 40:1727-1728